bioMérieux is a prominent player in alternative sterility testing methods, with a strong focus on inorganic growth strategies to maintain and expand its market leadership. The company's acquisition of Specific Diagnostics in May 2022 enhances its position in antimicrobial resistance and global clinical microbiology. bioMérieux's innovative products, including BACT/ALERT and SCANRDI, are pioneers in rapid microbiological methods, reducing sterility testing timelines from the traditional 11-14 days to just 4 hours.